Wugen, a Sant Louis MO- and San Diego CA-based clinical stage biotechnology company, raised $172M in Series B funding.
The round was led by Abingworth and Tybourne Capital Management with participation from Fidelity Management & Research Company, Intermediate Capital Group (ICG), Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital, Falcon Edge Capital, RiverVest Venture Partners, LYZZ Capital, Lightchain Capital.
The company intends to use the funds to support the clinical development of its memory natural killer (NK) cell platform and advance ongoing trials for patients with severe acute myelogenous leukemia (AML) and other oncology indications, as well as to advance its broader pipeline of next-generation products into the clinic.
Led by Dan Kemp, Wugen provides a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat a broad range of hematological and solid tumor malignancies. In addition, the company is developing a pipeline of programs targeting solid tumor indications.
FinSMEs
17/07/2021